drugset / Trial / NCT05438706
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of chidamide in combination with camrelizumab and carboplatin or capecitabine in the second and third line treatment of relapsed/metastatic triple-negative breast cancer
Timeline
- Start
- 2022-07-10
- Primary completion
- 2023-11-10
- Completion
- 2024-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |